在Venetoclax单一治疗后长期完全缓解的囊性等离子细胞质细胞瘤
Yohei Sasaki1, So Murai2, Eisuke Shiozawa2
1Division of Hematology, Department of Medicine, Showa University School of Medicine, Tokyo, JPN.
Cureus
|February 19, 2024
概括
威尼托克拉克斯 (VEN) 单一治疗可能为MYC阴性形血细胞状树突细胞瘤 (BPDCN) 的老年患者提供长期缓解. 这种方法遵循VEN和阿扎西提丁诱导,对这种罕见的血液性恶性瘤显示出希望.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 囊性等离子细胞状树突细胞瘤 (BPDCN) 是一种罕见的,具有侵略性的血液性恶性瘤,预后不佳,治疗选择有限.
- 密集化疗不适合老年或脆弱的BPDCN患者,需要使用替代治疗策略.
- 作为BCL2抑制剂的Venetoclax (VEN) 在BPDCN细胞中显示出体外敏感性,类似于其在急性髓性白血病 (AML) 中的使用.
研究的目的:
- 评估Venetoclax (VEN) 单一疗法的疗效,作为对囊性血细胞突变细胞瘤 (BPDCN) 的维持治疗.
- 探索VEN在管理BPDCN中的作用,特别是在不适合强化化疗的老年患者中.
- 调查BPDCN亚型 (MYC+与MYC-) 对治疗反应的潜在影响.
主要方法:
- 一个老年患者MYC阴性BPDCN的案例研究.
- 用Venetoclax (VEN) 和azacitidine进行诱导化疗.
- 维护疗法与VEN单一治疗.
主要成果:
- 患者实现了长期的完全缓解.
- 作为维持治疗,VEN单一治疗被很好地容忍.
- 针对MYC负的BPDCN亚型对基于VEN的疗法做出了良好的反应.
结论:
- 威尼托克拉克斯 (VEN) 单一疗法可以成为老年患者的有效维护策略,这些老年患者患有MYC阴性囊性血细胞突变细胞瘤 (BPDCN).
- 这种方法为不符合密集化疗条件的BPDCN患者提供了可行的治疗选择.
- 需要进一步研究VEN在不同BPDCN亚型中的疗效.
更多相关视频
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
相关概念视频
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...